Bridging the
Drug Discovery Path with Translatable Neuroscience
NeuCyte is an innovative biotechnology company focused on CNS drug discovery.
Based on its proprietary SynFire® technology for generating human iPSC-derived neurons, NeuCyte has developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. The team is actively pursuing drug discovery programs on Alzheimer's disease, ALS, Epilepsy, Fragile X Syndrome and more.
Our Unique Approach
The high attrition rate of novel CNS drugs during clinical development has been a major challenge to the pharmaceutical industry. This is largely attributed to the lack of biologically relevant models to study functional links between target and phenotype.
NeuCyte’s mission is to accelerate and optimize CNS drug discovery by developing more predictive assays and platforms for phenotypic screening.
SynFire Technology Platform
®
Based on the advantageous SynFire technology for generating human induced pluripotent stem cell (iPSC)-derived induced neuronal cells (iNs), NeuCyte has developed a proprietary in vitro human neural platform for complex electrophysiological and morphological readouts suited for target identification and validation, efficacy testing and neurotoxicity assessment.
Using patient-derived and genetically engineered defined neural cell types, NeuCyte builds unique cell-based assays for modeling neurological and neurodegenerative disorders.
Latest News
NeuCyte exhibits and presents at the Society of Toxicology annual meeting in Nashville
_edited.png)
Adam Caar
Nashville, Tennessee
March 21, 2023
Exhibitor Hosted Session: Next Generation Simplified iPSC Neuron-Based Neurotoxicity Assessment Assay with Affordability and Efficiency
Speakers:
Hui Liu, PhD, Head of Drug Discovery, NeuCyte
Martin Nicholson, PhD, Lead Scientist, NeuCyte
NeuCyte presents a scientific poster at the Alzheimer's Association International Conference
Adam Caar
San Diego, California
July 31 - August 3, 2022.
Development of iPSC-derived Alzheimer Disease (AD) platforms for phenotypic screening
NeuCyte exhibits and presents at the Society of Toxicology annual meeting in San Diego
Adam Caar
San Diego, California
March 29, 202
Exhibitor Hosted Session: Establishing an In Vitro Assay for Effectively Predicting Neurotoxicity Risk Using Human iPSC-Derived Neurons
Speaker:
Hui Liu, PhD, Head of Drug Discovery, NeuCyte
NeuCyte and KIF1A.ORG Enter Collaboration Agreement
Adam Caar
San Carlos, California, USA, August 17th, 2021 – NeuCyte, Inc., an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into a research collaboration agreement with KIF1A.ORG.
NeuCyte and Mount Sinai Enter Collaboration Agreement
Adam Caar
Developer
San Carlos, California, USA, January 19, 2021 - NeuCyte, Inc., an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into a research collaboration agreement with the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai.
Looking for an exciting and rewarding career opportunity?
![NeuCyte-Logo_original_blue[37082].png](https://static.wixstatic.com/media/d894e0_84ed1e7d403b4fb3a0d32e9d5b41fe61~mv2.png/v1/fill/w_178,h_69,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/NeuCyte-Logo_original_blue%5B37082%5D.png){kind=logo}
Adam Caar
Take on an exciting journey to accelerate and optimize drug discovery with fellow neuroscientists
Leave your mark, Improve lives
Developer